Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Axsome Therapeutics (NASDAQ:AXSM) had its target price boosted by equities researchers at Morgan Stanley from $217.00 to $242.00 in a research report issued to clients and investors on Tuesday, MarketBeat reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 6.51% from the company’s previous close.

Other analysts also recently issued reports about the company. Deutsche Bank Aktiengesellschaft set a $280.00 price objective on Axsome Therapeutics in a research report on Tuesday. Mizuho raised their price objective on Axsome Therapeutics from $228.00 to $310.00 and gave the stock an “outperform” rating in a research report on Tuesday. Leerink Partners raised their price objective on Axsome Therapeutics from $150.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 28th. Oppenheimer set a $280.00 target price on Axsome Therapeutics in a report on Monday. Finally, UBS Group raised their target price on Axsome Therapeutics from $251.00 to $259.00 and gave the company a “buy” rating in a report on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Axsome Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $251.89.

Axsome Therapeutics Price Performance

NASDAQ AXSM traded up $3.51 during mid-day trading on Tuesday, hitting $227.21. The stock had a trading volume of 357,508 shares, compared to its average volume of 699,103. The firm’s 50 day moving average is $170.95 and its 200 day moving average is $162.68. Axsome Therapeutics has a twelve month low of $96.09 and a twelve month high of $234.29. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.55 and a quick ratio of 1.48. The stock has a market capitalization of $11.69 billion, a price-to-earnings ratio of -61.57 and a beta of 0.59.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 28.69% and a negative return on equity of 232.61%. The firm had revenue of $191.20 million during the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics’s quarterly revenue was up 57.4% on a year-over-year basis. Equities research analysts forecast that Axsome Therapeutics will post -1.06 earnings per share for the current fiscal year.

Insider Activity

In other Axsome Therapeutics news, Director Mark Coleman sold 25,000 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $161.11, for a total value of $4,027,750.00. Following the transaction, the director owned 47,140 shares in the company, valued at $7,594,725.40. The trade was a 34.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Mark L. Jacobson sold 35,378 shares of the business’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $161.88, for a total value of $5,726,990.64. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 67,878 shares of company stock worth $11,122,891. 22.30% of the stock is owned by corporate insiders.

Institutional Trading of Axsome Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Axsome Therapeutics by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock worth $2,557,000 after purchasing an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp lifted its position in shares of Axsome Therapeutics by 2,407.9% during the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after purchasing an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Axsome Therapeutics by 38.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after purchasing an additional 84,151 shares during the last quarter. Caxton Associates LLP acquired a new position in shares of Axsome Therapeutics during the 1st quarter worth about $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Axsome Therapeutics by 29.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after purchasing an additional 17,250 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Key Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Large analyst upgrade: Mizuho raised its price target to $310 and kept an “outperform” rating — the biggest upside among recent broker moves and a key driver of bullish sentiment. Mizuho PT Raise
• Positive Sentiment: Wells Fargo lifted its target to $255 and placed AXSM at “overweight,” adding institutional validation to the rally. Wells Fargo PT Raise
• Positive Sentiment: Robert W. Baird raised its target to $246 and reiterated an “outperform” rating, providing further analyst support. Baird PT Raise (Benzinga) Baird PT Raise (The Fly)
• Positive Sentiment: Pipeline/regulatory progress and product updates highlighted in the company release: AUVELITY approved for agitation associated with dementia due to Alzheimer’s disease; NDA submitted for AXS?12 (cataplexy in narcolepsy); AXS?20 added to the pipeline — these items support longer?term revenue upside. Company Business Update & Q1 Release
• Neutral Sentiment: Investor access: Axsome will participate in several investor conferences (BofA Heath Care Conference, fireside chat, etc.), which may increase visibility and liquidity but are informational in nature. Investor Conferences
• Neutral Sentiment: Coverage consensus: Brokerages show a “Moderate Buy” consensus, reflecting generally favorable analyst sentiment that underpins recent upgrades. Consensus Coverage
• Negative Sentiment: Q1 results were mixed: revenue of $191.2M (up 57% y/y) roughly met estimates, but EPS missed materially (loss of $1.26 vs. est. -$0.85). Management provided growth commentary, yet some analysts noted sequential sales declines for Auvelity and Sunosi, tempering near?term expectations. Q1 Results & Transcript
• Negative Sentiment: Critical analyst take: a Seeking Alpha review flagged that management’s peak revenue targets may be ambitious given current product dynamics and competitive pressures — a cautionary note for valuation. Earnings Review (Seeking Alpha)

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.